Chemical Property of (2R,3S)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate
Chemical Property:
- Vapor Pressure:6.39E-13mmHg at 25°C
- Melting Point:232-235° (dec); mp 229-232° (dec) (Ohashi)
- Refractive Index:1.692
- Boiling Point:549.8 °C at 760mmHg
- PKA:2.09±0.24(Predicted)
- Flash Point:286.3 °C
- PSA：124.01000
- Density:1.608 g/cm3
- LogP:0.24340
- Storage Temp.:?20°C
- Solubility.:DMSO: ≥3mg/mL
- XLogP3:-3.3
- Hydrogen Bond Donor Count:4
- Hydrogen Bond Acceptor Count:5
- Rotatable Bond Count:2
- Exact Mass:213.06372245
- Heavy Atom Count:15
- Complexity:229
- Purity/Quality:
-
99%, *data from raw suppliers
L-threo-Droxidopa *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xi
- Hazard Codes:Xi
- Statements:
36/37/38
- Safety Statements:
26
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:C1=CC(=C(C=C1C(C(C(=O)[O-])[NH3+])O)O)O
- Isomeric SMILES:C1=CC(=C(C=C1[C@@H]([C@H](C(=O)[O-])[NH3+])O)O)O
-
Description
Droxidopa is a synthetic amino acid precursor of (-)-norepinephrine which is absorbed
from the gut and metabolized to norepinephrine. In Parkinsonian patients, droxidopa
added to existing levodopa/decarboxylase inhibitor therapy produces significant
improvements in retropulsion, dysarthria and muscular rigidity refractory to other
treatments; however, tremor was unaffected. Droxidopa (L-DOPS) is a synthetic precursor and prodrug of the neurotransmitter norepinephrine. It is transformed into norepinephrine through the action of DOPA decarboxylase. L-DOPS increases norepinephrine levels in the rat heart following intraperitoneal administration and in the brain following intracerebroventricular administration at doses of 125 and 100 μg/animal, respectively. It increases arterial pressure and mesenteric arterial resistance in rats with ligated portal vein or biliary ducts when used at doses of 25-50 mg/kg. L-DOPS crosses the blood brain barrier, however, its effects can be blocked by the peripherally-restricted DOPA decarboxylase inhibitor carbidopa , indicating that the mechanism is peripheral. Formulations containing droxidopa are used in the treatment of neurogenic orthostatic hypotension.
-
Uses
The L-threo-form Droxidopa. A synthetic amino acid precursor of Norepinephrine (N674500). Antiparkinsonian. Droxidopa is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline). L-DOPS has been administered for clinical trial studies in mice with amyloid pathology.
